GSK’s (GSK) Buy Rating Reiterated at Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday,Digital Look reports. They presently have a GBX 2,100 price objective on the stock. Jefferies Financial Group’s price objective points to a potential upside of 10.37% from the stock’s current price.

Several other equities analysts also recently issued reports on GSK. Berenberg Bank lifted their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a report on Monday, November 24th. JPMorgan Chase & Co. raised their price objective on shares of GSK from GBX 1,400 to GBX 1,500 and gave the stock an “underweight” rating in a report on Friday, November 7th. Finally, Shore Capital reissued a “buy” rating on shares of GSK in a report on Thursday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of GBX 1,762.

GSK Price Performance

LON:GSK traded up GBX 1.25 during mid-day trading on Wednesday, hitting GBX 1,902.75. The company’s stock had a trading volume of 7,630,360 shares, compared to its average volume of 6,804,678. The company has a market capitalization of £76.76 billion, a price-to-earnings ratio of 14.31, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. GSK has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 1,909.73. The stock has a fifty day moving average of GBX 1,805.21 and a 200-day moving average of GBX 1,595.16.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities analysts forecast that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity

In related news, insider Jonathan Symonds purchased 1,650 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was acquired at an average price of GBX 1,810 per share, with a total value of £29,865. Also, insider Wendy Becker acquired 441 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was bought at an average price of GBX 1,809 per share, with a total value of £7,977.69. Company insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.